Pasithea Therapeutics Files Proxy Statement
Ticker: KTTAW · Form: DEF 14A · Filed: May 28, 2024 · CIK: 1841330
| Field | Detail |
|---|---|
| Company | Pasithea Therapeutics CORP. (KTTAW) |
| Form Type | DEF 14A |
| Filed Date | May 28, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, shareholder-meeting
Related Tickers: PASI
TL;DR
PASI proxy filed for June 26 meeting. Standard shareholder stuff.
AI Summary
Pasithea Therapeutics Corp. filed a definitive proxy statement (DEF 14A) on May 28, 2024, for its annual meeting on June 26, 2024. The company, incorporated in Delaware with its principal office in Venice, CA, is in the pharmaceutical preparations industry. This filing is a standard procedural document for the upcoming shareholder meeting.
Why It Matters
This filing outlines the agenda and proposals for Pasithea Therapeutics' shareholder meeting, which could include votes on directors, executive compensation, or other corporate matters that impact the company's direction.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain new financial information or material events.
Key Players & Entities
- Pasithea Therapeutics Corp. (company) — Registrant
- 20240528 (date) — Filing Date
- 20240626 (date) — Meeting Date
- 2110 NARCISSUS CT, VENICE, CA 90291 (address) — Business Address
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, detailing the agenda and any proposals to be voted upon.
When is the shareholder meeting for Pasithea Therapeutics?
The shareholder meeting for Pasithea Therapeutics is scheduled for June 26, 2024.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on May 28, 2024.
Where is Pasithea Therapeutics Corp. headquartered?
Pasithea Therapeutics Corp.'s business and mailing address is 2110 Narcissus Ct, Venice, CA 90291.
What is the Standard Industrial Classification (SIC) code for Pasithea Therapeutics Corp.?
The Standard Industrial Classification code for Pasithea Therapeutics Corp. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,430 words · 18 min read · ~15 pages · Grade level 12.3 · Accepted 2024-05-28 09:00:12
Key Financial Figures
- $0.0001 — ompany’s common stock, par value $0.0001 per share (the “Common Stock
Filing Documents
- ea0205641-01.htm (DEF 14A) — 777KB
- tpasithea_logo.jpg (GRAPHIC) — 94KB
- tproxy_001.jpg (GRAPHIC) — 903KB
- tproxy_002.jpg (GRAPHIC) — 832KB
- 0001213900-24-046814.txt ( ) — 3298KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION   17
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS   24 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS   26 PROPOSAL NO. 2 — RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM   28 PRINCIPAL ACCOUNTANT FEES AND SERVICES   29 AUDIT COMMITTEE REPORT   30 ADDITIONAL INFORMATION   31 i Table of Contents PASITHEA THERAPEUTICS CORP. PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS May 28 , 2024 INTRODUCTION This Proxy Statement provides information for stockholders of Pasithea Therapeutics Corp. (“we,” “us,” “our,” “Pasithea” and the “Company”) as part of the solicitation of proxies by the Company and its Board of Directors (the “Board”) from holders of the outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for use at the Company’s annual meeting of stockholders to be held in a virtual format at www.virtualshareholdermeeting.com/KTTA2024 at 9:00 a.m. Eastern Time on June 26, 2024, and at any adjournments or postponements thereof (the “Annual Meeting”). At the Annual Meeting, stockholders will be asked to vote either directly or by proxy on the following matters discussed herein: 1.        Election of the director nominee named in this Proxy Statement to hold office until the annual meeting of stockholders in accordance with the class of director to which such nominee will be assigned; 2.        Ratification of the appointment of Marcum LLP (“Marcum”) as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and 3.        Transac